A recent study led by DCI researchers sheds light on how patients with multiple myeloma weigh the risks and benefits of two promising treatment options: CAR T-cell therapy and bispecific T-cell engagers. https://t.co/impUIOreJH @DukeHealth | @DukeMedSchool

What’s Best for Breasts? 💗 Join us for a free breast health education event: 🗓️ Oct. 11 | 🕗 8AM–3PM 📍 Duke Trent Semans Center, Durham ✅ Expert talks, resources, lunch & parking included! 🔗 Register: https://t.co/6W0HIgeDpP #CommunityHealthDuke | #BreastCancer | @DukeCancer

This #BreastCancerAwarenessMonth, see how @DukeCancer Dr. Carey Anders is providing care to women like Jamie Branham through groundbreaking research & compassionate care. 🩷 📺 Watch her story on PBS: https://t.co/jWJPzcOUYF #CommunityHealthDuke | #WomenInSTEM | @DukeMedSchool

Interested in targeting the prostate cancer surfaceome? See our review out today in @pcan_journal led by two outstanding GU fellows Bilal Ashraf and Jane McKenzie from @DukeCancer @DukeGUCancer and @PeterMacCC

Congrats to the newest Fellows of @AmCollSurgeons , absolute rockstars in their field, @DukeSurgOnc ‘s very own @globalsurgallie and @suziehillmd ! @DukeSurgery @DukeHealth @DukeCancer #FACS

DCI's Nicholas DeVito, MD, spoke with @Medscape about the rising rate of early-onset #GastrointestinalCancer in people under 50 and how clinicians can help counter that trend. https://t.co/XQO6IpoADA @DukeHealth

A new study reveals that small cell #LungCancer likely begins in basal stem cells rather than in neuroendocrine cells, marking a major shift in the understanding of this aggressive disease. https://t.co/HxzCkuOuLY @DukeHealth | @DukeMedSchool | @Duke_PCB

DCI's @DianeReidyLagun and @JenniferPlichta were named among the 100 Influential Women in Oncology to Follow on Social Media by @oncodaily. https://t.co/zJmxD6Ag1K

DCI's David Van Mater, MD, PhD, created a program to better support children with cancer predisposition syndromes and their families by developing a clinical pathway to genetic testing, monitoring, and care. https://t.co/GtmG5WkFdz @DukeHealth | @Duke_Childrens

DCI's Annick Desjardins, MD, spoke with @WRAL about glioblastoma following the death of Today show host Sheinelle Jones' husband. https://t.co/BJK5pgc4ov @DukeHealth | @prtbtcatduke

A new study sheds light on a critical treatment decision facing older women diagnosed with early-stage, hormone receptor-positive #BreastCancer: whether to pursue radiation therapy or endocrine therapy following lumpectomy. https://t.co/2VY2L6vOkY @DukeHealth | @DukeMedSchool

Congratulations to DCI's Chang-Lung Lee, PhD, and Manisha Palta, MD, on receiving a U01 grant from @NIAIDNews. Their research will focus on radiation-induced heart disease. https://t.co/BW3yLYqfxf @DukeRadOnc | @DukeMedSchool

Congratulations to DCI's Laura Alder, MD, on receiving the 2025-2026 Lung Cancer Research Fellowship grant from @LC_Initiative_! Alder's study will examine how radiation impacts non-small cell #LungCancer patients. https://t.co/iX4608Sb17 @DukeHealth | @DukeMedSchool

A new study reveals one in 12 patients who are diagnosed with two or more different types of cancer were born with a mutation in a known cancer risk gene. This could reshape how genetic testing is offered to cancer patients. https://t.co/OJFl5T2OCK @DukeHealth | @DukeGUCancer

The first patient has been enrolled in the PROPEL Registry, a multi-center study on the Aliya Pulsed Electric Field ablation system. DCI's Kamran Mahmood, MD, completed this first case. https://t.co/BpygidBtiB #LungCancer | @DukeHealth | @DukeMedSchool

Achieving the best outcomes for patients with esophageal cancer takes a team approach. “Our multidisciplinary approach brings patients the combined expertise of multiple disciplines and packages it so they receive multi-modal, high-quality care." - Dr. Hai Viet-Nguyen Salfity

Looking For a Crash Course in Tumor Immunology and Immunotherapy? - Nicholas DeVito https://t.co/Urkee5ME5y @DukeCancer #Immunotherapy #ImmuneOnc #TumorImmunology #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

PSA nadir predicts outcomes in metastatic hormone-sensitive #ProstateCancer patients. @hannahdzmd @DukeCancer joins @neerajaiims @huntsmancancer discussing research from the IRONMAN registry examining PSA responses and outcomes in metastatic hormone-sensitive prostate cancer

Duke Cancer Institute offers comprehensive treatment for esophageal cancer and other esophageal diseases. Read more ➡️ https://t.co/ICDSOcR9Tr @DukeCancer

Congratulations to DCI's Kris Wood, PhD, on receiving this year's All-Star Translational Cancer Research Grant from @TheVFoundation. Wood's research will focus on drugs that can kill residual #LungCancer cells. https://t.co/3BU9H2Il99 @DukeHealth | @Duke_PCB